Drug Giant AstraZeneca Launches Evinova to Quicken Clinical Trials - Decrypt


21 Nov 2023 1:03 AM

Evinova aims to use AI to design studies, automate cost calculations, and determine feasibility for drug testing....

  • AstraZeneca has announced the spin-off of a new digital health company called Evinova.
  • Evinova will operate independently within the AstraZeneca ecosystem and focus on developing AI-enabled digital technologies for medicine development.
  • The digital health market is projected to be worth $900 billion by 2032, and AstraZeneca believes progress in this field is crucial for reducing healthcare costs.
  • Evinova's initial focus will be on designing and running clinical trials, with the help of artificial intelligence (AI).
  • AI can assist in study design, automate cost calculations, determine trial feasibility, and speed up decision-making processes.
  • Other tech giants like Microsoft, Google, Amazon, and Meta have also heavily invested in AI.
  • AI models have shown potential in diagnosing and treating diseases, such as CNS tumors and cancer cells.
  • Evinova aims to deliver science-based, evidence-led, and human experience-driven solutions to improve patient experience and outcomes.

The overall sentiment of the article is positive. It highlights the potential benefits of digital health, AI-enabled technologies, and the launch of Evinova in improving patient care and healthcare transformation.

Go to publisher site

You May Ask

What is the purpose of AstraZeneca's spin-off company, Evinova?How does AstraZeneca believe digital solutions can accelerate medicine development?What are some examples of digital health technologies?How can AI assist in the design and execution of clinical trials?What are the potential applications of AI in healthcare, as mentioned in the article?

Suggested Reads